/
Neurology
Alzheimer Disease
43
Pipeline Programs↗
87
Active Trials↗
34
Companies Involved↗
Alzheimer disease is a moderately active landscape with 43 programs across 34 companies. The most active players are Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Johnson & Johnson. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 111
Phase 214
Phase 34
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
22 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 77% of 43 pipeline programs.
Analysis
Trial Status
147
clinical trials
Recruiting50 · 34%
Completed46 · 31%
Active, not recruiting19 · 13%
Not yet recruiting13 · 9%
Terminated10 · 7%
Enrolling by invitation5 · 3%
Other4 · 3%
Clinical Trials
Trial Activity
147 trials
Daridorexant for Alzheimer Disease Prevention
Recruiting·—·Phase 2·NCT07213349·240 enrolled
Losing Specificity: the Role of the Locus Coeruleus in Age-related Distractibility
Recruiting·VVirginia Polytechnic Institute and State University·Preclinical·NCT05574634·200 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)